Native human GHRH(1-44) is rapidly degraded by the enzyme dipeptidyl peptidase-IV (DPP-IV), which cleaves it within minutes of release into circulation. Tesamorelin adds a trans-3-hexenoyl group at the N-terminus, blocking DPP-IV cleavage and extending the functional half-life of the peptide. The amino acid sequence remains otherwise identical to native GHRH — Tesamorelin acts on the same GHRH receptor with the same downstream pharmacology.

Tesamorelin is the only GHRH-analog peptide approved by the FDA for any indication — originally for the reduction of excess abdominal fat in HIV-associated lipodystrophy, marketed under the brand name Egrifta. That approval applies only to the specific clinical indication. This Elixser product is research-grade material intended for laboratory research only — not the FDA-approved drug product, not for human use, and not for any indication outside the original research context.

Every lot is tested by reverse-phase HPLC and certified at ≥99% purity. The Certificate of Analysis lists the exact lot purity (most lots run between 99.5% and 99.9%). Your COA ships with the vial and is also retrievable by lot number through our online verifier.

Testing is done by BioRegen Analytical, an independent third-party lab. Every batch goes through HPLC purity, LC-MS identity confirmation, sterility screening, and LAL endotoxin testing. The signed Certificate of Analysis ships with each vial. Same lot number, same COA, every time.

Made in the USA. Synthesized in a US cGMP-aligned facility. Tested by a US-based independent lab. Shipped from US fulfillment.

Orders ship via 2-day expedited delivery from US fulfillment. Free over $150. Vials are sealed, packaged with insulation, and shipped in tamper-evident packaging. Tracking number is sent the same day your order leaves the warehouse.